Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Post-inspection response program: Beginning Sept. 15, FDA will consider industry responses to Form 483 inspection reports received within 15 days of the report's release when deciding whether to send a warning letter, FDA explains in an Aug. 11 Federal Register 1notice. Timely responses do not preclude FDA from issuing a warning letter. FDA Commissioner Margaret Hamburg announced the 15-day post-inspection deadline for company responses to FDA's inspection findings at a Food and Drug Law Institute meeting Aug. 6 (2"The Gray Sheet" Aug. 10, 2009). FDA plans to test out the response review program for 18 months and then decide whether to implement it permanently

You may also be interested in...



Abbott's New Glucose Test Strips Are First To Address Fatal Product Flaw

With a little extra push from FDA, Abbott gained 510(k) clearance May 14 for its new FreeStyle Lite blood glucose test strips, designed to remedy a potentially life threatening flaw in the product

Abbott's New Glucose Test Strips Are First To Address Fatal Product Flaw

With a little extra push from FDA, Abbott gained 510(k) clearance May 14 for its new FreeStyle Lite blood glucose test strips, designed to remedy a potentially life threatening flaw in the product

Facility Registration, Import Problems Keep CDRH Compliance Office Busy

CDRH Compliance Director Tim Ulatowski gave an update last week on activities at his office, including import safety efforts and a notable warning letter push

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel